Home Tags SGN-CD33A

Tag: SGN-CD33A

U.S. FDA Lifts Clinical Hold Phase I Trials of Vadastuximab Talirine

The U.S. Food and Drug Administration (FDA) confirmed today that it has lifted the clinical hold on phase 1 trials of vadastuximab talirine (SGN-CD33A;...

Clinical Hold on Several Phase I Trials of Vadastuximab Talirine; Enrollment...

Earlier today Seattle Genetics, an innovative biotechnology company that develops and commercializes novel antibody-based therapies for the treatment of cancer, confirmed that it has...

Study Shows 76% Objective Response Rate in Newly Diagnosed Acute Myeloid...

Phase I clinical data from a study evaluating vadastuximab talirine, also known as SGN-CD33A or 33A in combination with hypomethylating agents (HMAs; azacitidine, decitabine) in...

Vadastuximab Talirine Demonstrates Encouraging Anti-leukemic Activity in Acute Myeloid Leukemia

Several presentations at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, Florida, December 5-8, 2015, evaluating vadastuximab...

Phase I/II Clinical Trial of Vadastuximab Talirine Initiated in Patients with...

Earlier today Seattle Genetics, a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer,  confirmed that...

SGN-CD33A Demonstrates Encouraging Antitumor Activity in Acute Myeloid Leukemia

To-date, the treatment of acute myeloid leukemia or  AML remains general unsatisfactory.  Both the medical and scientific communities are looking for urgently needed novel...

New CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Anti-tumor Activity in...

Preclinical data from SGN-CD33A (Seattle Genetics, Inc), a novel CD33-directed antibody-drug conjugate (ADC) in development for the treatment of acute myeloid leukemia (AML) presented at...